An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction

Clinical Therapeutics

Volumn 23, Issue 8, 2001, Pages 1260-1271

  Mulhall, John P ^a   Bukofzer, Stanley ^b   Edmonds, Anthony L ^c   George, Michael ^d  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b ABBOTT LABORATORIES   (United States)

^c TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^d Takeda Europe R and D Centre   (United Kingdom)

Author keywords

Apomorphine; Dopamine agonist; Dose optimization; ED; Erectile dysfunction

Indexed keywords

APOMORPHINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PENIS ERECTION; PHASE 3 CLINICAL TRIAL; SEXUAL INTERCOURSE;

EID: 0034878165     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80105-3     Document Type: Article

References (12)

1. Impotence: NIH Consensus Development panel on impotence
2. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study
3. 2-receptor antagonist
4. Structure and function of dopamine receptors
5. Neuromodulation of penile erection: An overview of the rate of neurotransmitters and neuropeptides
6. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction
7. Apomorphine: An update of clinical trial results
8. The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction
9. Sildenafil for erectile dysfunction
10. Oral pharmacotherapy for erectile dysfunction: Current perspectives
11. The epidemiology and pathophysiology of erectile dysfunction
12. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction